What is Spectrum Pharmaceuticals, Inc. (SPPI)?

Spectrum Pharmaceuticals, Inc. (SPPI) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of SPPI?

The current price of SPPI is $1.03. Prices are updated in real time on Stocks360.

What is SPPI's price-to-earnings (PE) ratio?

SPPI's trailing twelve-month PE ratio is -2.38, based on current price and earnings per share data available on Stocks360.

What is SPPI's market capitalization?

SPPI's market capitalization is $210,377,146.00, placing it in the small-cap tier.

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.03

Market Cap

$210.38M

PE (TTM)

-2.38

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.14

Day Range

$0.97 – $1.06

52-wk Range

$0.32 – $1.57

Avg Volume

N/A

Volume

4.85M

Spectrum Pharmaceuticals, Inc. (SPPI) is a publicly traded company in the Healthcare sector. Latest price: $1.03. Market cap $210.38M. Trailing PE -2.38. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 10, 2023

EPS $-0.17 vs est. $-0.04

Missed by $0.13

Proprietary Signals

Signal snapshot temporarily unavailable.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headqua…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.38×
P/S (TTM)	20.80×
P/B	6.73×
P/FCF (TTM)	-2.16×
EV / EBITDA	-2.60×
EV / Sales	19.72×
Earnings Yield	-41.58%
Free Cash Flow Yield	-46.23%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$199.44M
Revenue (TTM)	$10.11M
Net Income (TTM)	-$87.49M
Free Cash Flow (TTM)	-$96.26M
Net Debt	-$10.94M
Working Capital	$58.33M
Gross Margin	82.28%
Operating Margin	-718.78%
Net Margin	-772.24%
Return on Equity	-207.06%
Return on Invested Capital	-118.37%